Bevacizumab, Aflibercept or Ramucirmab combined with chemotherapy as second-line treatment for metastatic colorectal cancer following progression with Bevacizumab in first-line therapy: A systematic review and indirect comparison.

被引：0
|
作者：
Zhang, Jianwei [1 ]
Cai, Yue [1 ]
Hu, Huabin [1 ]
Ling, Jiayu [1 ]
Xiao, Jian [1 ]
Deng, Yanhong [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14601
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer
    Qin, Shukui
    Deng, Yanhong
    Bi, Feng
    Liu, Tian Shu
    Liu, Yunpeng
    Zhang, Suzhan
    Xu, Jianming
    Shu Yongqian
    Xu, Nong
    Wu, Changping
    Wang, Xin
    Zhong, Haijun
    Feng, Jifeng
    He, Yulong
    Yang, Jianwei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
    Shun Yamamoto
    Kengo Nagashima
    Takeshi Kawakami
    Seiichiro Mitani
    Masato Komoda
    Yasushi Tsuji
    Naoki Izawa
    Kentaro Kawakami
    Yoshiyuki Yamamoto
    Akitaka Makiyama
    Kentaro Yamazaki
    Toshiki Masuishi
    Taito Esaki
    Takako Eguchi Nakajima
    Hiroyuki Okuda
    Toshikazu Moriwaki
    Narikazu Boku
    [J]. BMC Cancer, 21
  • [3] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [4] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
    Yamamoto, Shun
    Nagashima, Kengo
    Kawakami, Takeshi
    Mitani, Seiichiro
    Komoda, Masato
    Tsuji, Yasushi
    Izawa, Naoki
    Kawakami, Kentaro
    Yamamoto, Yoshiyuki
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Esaki, Taito
    Nakajima, Takako Eguchi
    Okuda, Hiroyuki
    Moriwaki, Toshikazu
    Boku, Narikazu
    [J]. BMC CANCER, 2021, 21 (01)
  • [5] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [6] Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
    Raquel Claramunt García
    Carmen Lucía Muñoz Cid
    Andrés Sánchez Ruiz
    Juan Francisco Marín Pozo
    [J]. European Journal of Clinical Pharmacology, 2022, 78 : 287 - 291
  • [7] Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
    Claramunt Garcia, Raquel
    Munoz Cid, Carmen Lucia
    Sanchez Ruiz, Andres
    Marin Pozo, Juan Francisco
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (02) : 287 - 291
  • [8] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    [J]. HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [9] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [10] Comparative analysis of the effectiveness of second-line bevacizumab plus chemotherapy in second-line therapy in metastatic colorectal cancer.
    Smagulova, Kaldigul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345